A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Programmable Macrophage Vesicle Based Bionic Self‐Adjuvanting Vaccine for Immunization against Monkeypox Virus
The emergence of monkeypox has become a global health threat after the COVID‐19 pandemic. Due to the lack of available specifically treatment against MPV, developing an available vaccine is thus the most prospective and urgent strategy. Herein, a programmable macrophage vesicle based bionic self‐adjuvanting vaccine (AM@AEvs‐PB) is first developed for defending against monkeypox virus (MPV). Based on MPV‐related antigen‐stimulated macrophage‐derived vesicles, the nanovaccine is constructed by loading the mature virion (MV)‐related intracellular protein (A29L/M1R) and simultaneously modifying with the enveloped virion (EV) antigen (B6R), enabling them to effectively promote antigen presentation and enhance adaptive immune through self‐adjuvant strategy. Owing to the synergistic properties of bionic vaccine coloaded MV and EV protein in defensing MPV, the activation ratio of antigen‐presenting cells is nearly four times than that of single antigen in the same dose, resulting in stronger immunity in host. Notably, intramuscular injection uptake of AM@AEvs‐PB demonstrated vigorous immune‐protective effects in the mouse challenge attempt, offering a promising strategy for pre‐clinical monkeypox vaccine development.
Programmable Macrophage Vesicle Based Bionic Self‐Adjuvanting Vaccine for Immunization against Monkeypox Virus
The emergence of monkeypox has become a global health threat after the COVID‐19 pandemic. Due to the lack of available specifically treatment against MPV, developing an available vaccine is thus the most prospective and urgent strategy. Herein, a programmable macrophage vesicle based bionic self‐adjuvanting vaccine (AM@AEvs‐PB) is first developed for defending against monkeypox virus (MPV). Based on MPV‐related antigen‐stimulated macrophage‐derived vesicles, the nanovaccine is constructed by loading the mature virion (MV)‐related intracellular protein (A29L/M1R) and simultaneously modifying with the enveloped virion (EV) antigen (B6R), enabling them to effectively promote antigen presentation and enhance adaptive immune through self‐adjuvant strategy. Owing to the synergistic properties of bionic vaccine coloaded MV and EV protein in defensing MPV, the activation ratio of antigen‐presenting cells is nearly four times than that of single antigen in the same dose, resulting in stronger immunity in host. Notably, intramuscular injection uptake of AM@AEvs‐PB demonstrated vigorous immune‐protective effects in the mouse challenge attempt, offering a promising strategy for pre‐clinical monkeypox vaccine development.
Programmable Macrophage Vesicle Based Bionic Self‐Adjuvanting Vaccine for Immunization against Monkeypox Virus
Lin, Weiqiang (author) / Shen, Chenguang (author) / Li, Mengjun (author) / Ma, Shengchao (author) / Liu, Chenxin (author) / Huang, Jialin (author) / Ren, Zuning (author) / Yang, Yuechao (author) / Zhao, Minghai (author) / Xie, Qiulin (author)
Advanced Science ; 12
2025-01-01
17 pages
Article (Journal)
Electronic Resource
English
Mechanically Tunable, Self-Adjuvanting Nanoengineered Polypeptide Particles
| British Library Online Contents | 2013
Vaccine Justice and Bioethical Reflections of COVID-19 Immunization in Malaysia
| DOAJ | 2022